Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophagitis Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Esophageal Clearance Times of Oral Budesonide Preparations

NCT02125851
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Xanthan Gum, Honey
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 21, 2026, 6:45 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Imaging of the Esophagus Using a SECM Capsule

NCT03546660
View directory record Official record
Conditions
Eosinophilic Esophagitis, Barrett Esophagus
Interventions
SECM capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 21, 2026, 6:45 AM EDT
Withdrawn Not applicable Interventional

Short Duration 6Fed Sponge For EoE Patients

NCT03354221
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Jul 21, 2026, 6:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia

NCT01028235
View directory record Official record
Conditions
Dysphagia
Interventions
Not listed
Lead sponsor
San Antonio Uniformed Services Health Education Consortium
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2009 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis

NCT02227836
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Allergy Patch Testing
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 21, 2026, 6:45 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

NCT07358234
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], budesonide oral suspension
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Jul 21, 2026, 6:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:

NCT07227506
View directory record Official record
Conditions
Gerd, Eosinophilic Esophagitis
Interventions
MuVI Esophageal mucosal impedance testing
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 21, 2026, 6:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)

NCT03228407
View directory record Official record
Conditions
Gastro Esophageal Reflux, Barrett Esophagus, Erosive Esophagitis
Interventions
Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI)
Procedure · Diagnostic Test
Lead sponsor
McGuire Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 21, 2026, 6:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucosal Impedance Balloon in Diagnosis and Treatment of Eosinophilic Esophagitis (EoE)

NCT02995395
View directory record Official record
Conditions
Eosinophilic Esophagitis, Healthy
Interventions
Mucosal Impedance Balloon catheter
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Jul 21, 2026, 6:45 AM EDT
Not listed No phase listed Observational

Fibrostenotic Eosinophilic Esophagitis: Assessment Tools

NCT02453126
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis

NCT00880906
View directory record Official record
Conditions
Suspected Eosinophilic Esophagitis
Interventions
Esophageal dilation, Steroid and Proton Pump Inhibitor Therapy
Procedure · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)

NCT02722148
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jul 21, 2026, 6:45 AM EDT
Withdrawn Early Phase 1 Interventional

CYP2C19 Genotype Predictor of Gastric Acid Suppression

NCT01824199
View directory record Official record
Conditions
Esophagitis
Interventions
Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

NCT05084963
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
IRL201104, Placebo
Drug
Lead sponsor
Revolo Biotherapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Little Rock, Arkansas • Murrieta, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 21, 2026, 6:45 AM EDT
Withdrawn No phase listed Observational

Eosinophilic Gastrointestinal Disorders Patient Registry

NCT01779154
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
esomeprazole magnesium (oral medication)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
39
States / cities
Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Jul 21, 2026, 6:45 AM EDT
Not listed Phase 1Phase 2 Interventional

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

NCT01129713
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
Interventions
Secretol, Nexium
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Sponge and Eosinophil Peroxidase (EPO) Staining

NCT03078023
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
swallowed sponge device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Mucosal Impedance and Eosinophilic Esophagitis

NCT01953575
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Mucosal Impedance, Upper Endoscopy
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jul 21, 2026, 6:45 AM EDT